← Back to Screener
Gyre Therapeutics, Inc. Common Stock (GYRE)
Price$6.29
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-26.76%
Price vs S&P 500 (4W)-15.79%
VGM Score42.13
Market Capitalization$610.09M
P/E Ratio (Annual)121.36x
All Metrics
P/CF (Annual)604.05x
Book Value / Share (Quarterly)$1.11
P/TBV (Annual)6.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)428.46%
Cash Flow / Share (Quarterly)$0.03
Price vs S&P 500 (YTD)-19.06%
Gross Margin (TTM)95.09%
Net Profit Margin (TTM)-5.44%
EPS (TTM)$-0.08
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-0.08
Revenue Growth (5Y)40.96%
EPS (Annual)$0.05
ROI (Annual)4.74%
Gross Margin (Annual)95.35%
Net Profit Margin (5Y Avg)-461.44%
Cash / Share (Quarterly)$0.55
P/E Basic Excl Extra (TTM)116.93x
Revenue Growth QoQ (YoY)2.09%
P/E Normalized (Annual)121.36x
ROA (Last FY)3.03%
Revenue Growth TTM (YoY)16.30%
EBITD / Share (TTM)$0.03
ROE (5Y Avg)-90.40%
Operating Margin (TTM)-0.12%
Cash Flow / Share (Annual)$-0.01
P/B Ratio6.02x
P/B Ratio (Quarterly)6.28x
Net Income / Employee (Annual)$8,100
EV / Revenue (TTM)4.89x
Net Interest Coverage (TTM)-14.38x
ROA (TTM)-3.98%
EPS Growth QoQ (YoY)215.45%
EV / EBITDA (TTM)231.16x
EPS Incl Extra (Annual)$0.05
Current Ratio (Annual)5.60x
Quick Ratio (Quarterly)3.87x
3-Month Avg Trading Volume0.09M
52-Week Price Return-21.08%
P/E Incl Extra (TTM)116.93x
Revenue / Employee (TTM)$189,400
Tangible BV / Share (Quarterly)$1.06
P/S Ratio (Annual)5.23x
Asset Turnover (Annual)0.70x
52-Week High$9.42
Operating Margin (5Y Avg)-459.73%
EPS Excl Extra (Annual)$0.05
CapEx CAGR (5Y)45.00%
Tangible BV CAGR (5Y)-17.70%
26-Week Price Return-18.84%
Quick Ratio (Annual)4.97x
13-Week Price Return-19.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.64x
Enterprise Value$572.59M
Revenue / Share Growth (5Y)-41.41%
Asset Turnover (TTM)0.73x
Book Value / Share Growth (5Y)-42.88%
Revenue / Employee (Annual)$188,700
Inventory Turnover (Annual)0.66x
Pretax Margin (Annual)12.38%
Cash / Share (Annual)$0.57
3-Month Return Std Dev57.21%
Gross Margin (5Y Avg)57.41%
Net Income / Employee (TTM)$-10,300
ROE (Last FY)4.74%
EPS Basic Excl Extra (Annual)$0.05
P/FCF (TTM)69.34x
Receivables Turnover (TTM)5.46x
EV / Free Cash Flow (TTM)188.72x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.08
Receivables Turnover (Annual)4.60x
ROI (TTM)-6.34%
P/S Ratio (TTM)5.21x
Pretax Margin (5Y Avg)-446.04%
Revenue / Share (Annual)$1.13
Tangible BV / Share (Annual)$1.09
Forward P/E195.13x
Price vs S&P 500 (52W)-45.44%
P/E Ratio (TTM)116.93x
EPS Growth TTM (YoY)-60.17%
Year-to-Date Return-10.91%
5-Day Price Return8.26%
EPS Normalized (Annual)$0.05
ROA (5Y Avg)-50.79%
Net Profit Margin (Annual)4.31%
Month-to-Date Return6.43%
Cash Flow / Share (TTM)$-18.23
EBITD / Share (Annual)$0.14
Operating Margin (Annual)9.85%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)141.26x
ROI (5Y Avg)-90.40%
P/E Excl Extra (TTM)116.93x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.08
P/TBV (Quarterly)6.58x
P/B Ratio (Annual)6.05x
Inventory Turnover (TTM)0.60x
Pretax Margin (TTM)0.48%
Book Value / Share (Annual)$1.16
Price vs S&P 500 (13W)-27.92%
Beta2.36x
P/FCF (Annual)35.25x
Revenue / Share (TTM)$1.28
ROE (TTM)-6.34%
52-Week Low$5.44
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.04est. -0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GYREGyre Therapeutics, Inc. Common Stock | D | C | C | $6.29 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Gyre Therapeutics is a commercial-stage biopharmaceutical company specializing in small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis. The company commercializes ETUARY, Avatrombopag, and Nintedanib, while advancing Hydronidone (F351) for metabolic dysfunction-associated steatohepatitis liver fibrosis and a pipeline of earlier-stage candidates in China. Primary revenue derives from ETUARY and generic pharmaceutical sales in mainland China.